These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31888870)
1. France removes state funding for dementia drugs. Walsh S; King E; Brayne C BMJ; 2019 Dec; 367():l6930. PubMed ID: 31888870 [No Abstract] [Full Text] [Related]
2. NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom? O'Brien JT Lancet Neurol; 2006 Dec; 5(12):994-6. PubMed ID: 17110274 [No Abstract] [Full Text] [Related]
3. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Winblad B; Hill S; Beermann B; Post SG; Wimo A Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():39-45. PubMed ID: 9305515 [No Abstract] [Full Text] [Related]
4. Harbinger of hope or commodity fetishism: "re-cognizing" dementia in an age of therapeutic agents. Graham JE Int Psychogeriatr; 2001 Jun; 13(2):131-4. PubMed ID: 11495389 [No Abstract] [Full Text] [Related]
5. Experts disagree over NICE's approach for assessing drugs. Hoey R Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791 [No Abstract] [Full Text] [Related]
6. Antidementia drugs: are they effective in improving quality of life for elderly persons with dementia? Homma A Int Psychogeriatr; 1995; 7(3):363-6. PubMed ID: 8821343 [No Abstract] [Full Text] [Related]
7. A systematic review of the cost-effectiveness of interventions for supporting informal caregivers of people with dementia residing in the community. Jones C; Edwards RT; Hounsome B Int Psychogeriatr; 2012 Jan; 24(1):6-18. PubMed ID: 21813034 [TBL] [Abstract][Full Text] [Related]
8. The relationship between elderly suicide rates and the affordability of psychotropic drugs. Shah A; Bhatia G Int Psychogeriatr; 2009 Feb; 21(1):204-5. PubMed ID: 18634616 [No Abstract] [Full Text] [Related]
9. Ethics and the anti-dementia drugs. Hughes JC Int J Geriatr Psychiatry; 2000 Jun; 15(6):538-43. PubMed ID: 10861921 [No Abstract] [Full Text] [Related]
10. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Fariello RG Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984 [No Abstract] [Full Text] [Related]
11. Diagnosing and treating dementia in German primary and specialized care between 2011 and 2015 . Michalowsky B; Kostev K; Iliffe S; Hoffmann W; Bohlken J Int J Clin Pharmacol Ther; 2018 Jul; 56(7):301-309. PubMed ID: 29701170 [TBL] [Abstract][Full Text] [Related]
19. Yokukansan treatment in chronic renal failure patients with dementia receiving hemodialysis: an open label study. Sumiyoshi H; Mantani A; Nishiyama S; Fujiwaki S; Ohta S; Masuda Y; Tomita Y; Tarumoto N; Yamawaki S Am J Geriatr Psychiatry; 2011 Oct; 19(10):906-7. PubMed ID: 21795962 [No Abstract] [Full Text] [Related]
20. Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Post SG; Beerman B; Brodaty H; Gaines AW; Gauthier SG; Geldmacher DS; Hill S; Homma A; Rossor MN; Whitehouse PJ; Winblad B Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():26-8. PubMed ID: 9305511 [No Abstract] [Full Text] [Related] [Next] [New Search]